Chardan Capital Issues Positive Forecast for Palvella Therapeutics (NASDAQ:PVLA) Stock Price

Palvella Therapeutics (NASDAQ:PVLA) had its target price increased by Chardan Capital from $73.00 to $110.00 in a research report report published on Friday morning,Benzinga reports. The firm currently has a buy rating on the stock.

A number of other research analysts also recently weighed in on PVLA. Raymond James Financial set a $54.00 price objective on shares of Palvella Therapeutics and gave the company an “outperform” rating in a research report on Tuesday, August 5th. Oppenheimer initiated coverage on Palvella Therapeutics in a report on Tuesday, September 9th. They set an “outperform” rating and a $85.00 price target on the stock. Weiss Ratings restated a “sell (d-)” rating on shares of Palvella Therapeutics in a research note on Wednesday, October 8th. Lifesci Capital began coverage on Palvella Therapeutics in a research report on Monday, August 4th. They set an “outperform” rating and a $90.00 price objective for the company. Finally, Stifel Nicolaus raised their target price on Palvella Therapeutics from $60.00 to $80.00 and gave the stock a “buy” rating in a research report on Wednesday, September 24th. One analyst has rated the stock with a Strong Buy rating, eleven have assigned a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $97.58.

Palvella Therapeutics Stock Performance

Shares of PVLA traded down $0.80 on Friday, hitting $77.83. 104,830 shares of the stock traded hands, compared to its average volume of 116,017. Palvella Therapeutics has a one year low of $11.17 and a one year high of $83.00. The company has a market capitalization of $860.80 million, a PE ratio of -20.54 and a beta of -0.05. The business has a 50 day simple moving average of $66.13 and a 200 day simple moving average of $42.75.

Palvella Therapeutics (NASDAQ:PVLA) last released its quarterly earnings data on Thursday, August 14th. The company reported ($0.86) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.78) by ($0.08). On average, equities analysts expect that Palvella Therapeutics will post -3.69 earnings per share for the current year.

Institutional Trading of Palvella Therapeutics

Several hedge funds have recently bought and sold shares of PVLA. Archer Investment Corp purchased a new position in shares of Palvella Therapeutics during the third quarter valued at about $28,000. Police & Firemen s Retirement System of New Jersey purchased a new stake in shares of Palvella Therapeutics in the second quarter worth about $37,000. AlphaQuest LLC bought a new position in Palvella Therapeutics during the third quarter valued at approximately $164,000. JPMorgan Chase & Co. grew its holdings in Palvella Therapeutics by 108,066.7% during the 2nd quarter. JPMorgan Chase & Co. now owns 3,245 shares of the company’s stock valued at $73,000 after buying an additional 3,242 shares in the last quarter. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. purchased a new position in Palvella Therapeutics during the 2nd quarter valued at approximately $85,000. Hedge funds and other institutional investors own 40.11% of the company’s stock.

Palvella Therapeutics Company Profile

Palvella Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases. Palvella Therapeutics Inc, formerly known as Pieris Pharmaceuticals Inc, is based in WAYNE, Pa.